财务表现 - Amphastar Pharmaceuticals (AMPH)在最近的季度盈利报告中每股盈利为0.88美元，超过了Zacks Consensus Estimate的0.87美元[1] - 这家专业制药公司在上一个季度预计每股盈利为0.70美元，实际盈利为1.15美元，超出预期64.29%[2] - Amphastar在2023年12月结束的季度实现了1.83%的营收增长，达到了1.7811亿美元，超过了Zacks Consensus Estimate[3] 股票表现 - Amphastar股票自年初以来下跌了约10.4%，而标普500指数上涨了6.5%[4] 投资前景 - 投资者关注的下一个问题是Amphastar的未来走势，特别是公司的盈利前景[5] - 投资者可以通过追踪盈利预期修订趋势来预测股票的短期走势[6] - 在最新的盈利报告发布之前，Amphastar的盈利预期修订趋势是混合的，目前的Zacks Rank为3（持有）[7] 行业排名 - 投资者应该注意行业前景对股票表现的影响，目前医药-通用药品行业在Zacks行业排名中处于倒数34%[8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ Commission File Number 001-36509 AMPHASTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 33-0702205 (State or other juri ...

EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023 Reports Net Revenues of $178.1 Million for the Three Months Ended December 31, 2023 RANCHO CUCAMONGA, CA – February 28, 2024 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full-year ended December 31, 2023. Fourth Quarter Highlights ● Net revenues of $178.1 million for the fourth quarter ● GAAP net income ...

Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $51.91, moving +1.29% from the previous trading session. This change lagged the S&P 500's 2.11% gain on the day. Meanwhile, the Dow gained 1.18%, and the Nasdaq, a tech-heavy index, added 2.96%. Shares of the specialty pharmaceutical company witnessed a loss of 7.19% over the previous month, trailing the performance of the Medical sector with its gain of 3.98% and the S&P 500's gain of 3.08%. Market participants will be closely following ...

投资者参考 - 投资者在做出股票买入、卖出或持有决策之前通常会参考华尔街分析师的推荐[1] - 经纪推荐并不总是能够准确指导投资者选择潜力最大的股票[4] Amphastar Pharmaceuticals (AMPH)推荐 - Amphastar Pharmaceuticals (AMPH)目前的平均经纪推荐值为1.40，介于强烈买入和买入之间[2] - 80%的推荐是强烈买入[3]

Drug stock Amphastar Pharmaceuticals (AMPH) has formed a cup base and settled down after a steep sell- off in January. Now, as an IBD Sector Leader, Amphastar stock is about 18% off its all-time high. X Amphastar develops injectable, inhalation and intranasal medical and insulin products. Its products are used mainly in hospitals and urgent care clinics. It also makes over-the-counter asthma inhaler Primatene Mist, along with emergency glucagon treatment kits for low blood sugar. Amphastar ranks No. 1 among ...

Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $55.61, moving +1.85% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.57%. At the same time, the Dow lost 0.14%, and the tech-heavy Nasdaq gained 1.25%. Prior to today's trading, shares of the specialty pharmaceutical company had gained 1.05% over the past month. This has lagged the Medical sector's gain of 2.05% and the S&P 500's gain of 5.07% in that time. Investors will be eagerly watching for the p ...

生物技术领域 - 生物技术领域是一个不断增长的领域，公司不断进行出色的研究、产品和解决方案，同时也在不断创新和为人类健康做出贡献[1] - Nkarta公司是一家大型生物制药公司，被许多投资者认为是该领域的领导者，他们采用改良的自然杀伤细胞(NK细胞)开发疗法，这是人体抵抗癌症和自身免疫性疾病的关键组成部分[2] - Nkarta公司最近获得了针对狼疮性肾炎的突破性细胞疗法NKX019的FDA批准，这是一项重大成就，有望改变自身免疫性疾病的治疗方式[4]

Amphastar Pharmaceuticals (AMPH) closed at $54.94 in the latest trading session, marking a -0.81% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.06%. At the same time, the Dow added 0.35%, and the tech-heavy Nasdaq lost 0.76%. Shares of the specialty pharmaceutical company witnessed a loss of 10.45% over the previous month, trailing the performance of the Medical sector with its gain of 1.65% and the S&P 500's gain of 3.36%. Analysts and investors alike will be kee ...

The U.S. economy showed robustness in 2023 while expanding at a healthy pace in the final three months and squashing recession fearmongering. The domestic economy displayed astounding resilience in the face of the Federal Reserve’s monetary tightening campaign to tame relentless price pressures. It continued to thrive, banking on the uptick in consumer outlays and strength in the labor market. The U.S. economy accelerated at an annualized rate of 3.3% in the final quarter of 2023, more than economists’ fore ...